
Why are federal lawmakers who support the 340B Drug Pricing Program introducing legislation that merely delays a Trump administration plan that would change how providers would access their savings – from the time of purchase to rebates after transactions – instead of prohibiting rebate conversion altogether? Last month, U.S. Representatives Rob Bresnahan (R-PA), Debbie Dingell (D-MI), Lois Frankel (D-FL), and Tracey Mann (R-KS) introduced the 340B Rebate Model Delay Act, which would delay the implementation of the rebate model pilot program until December 31, 2028. The crux of the bill makes no sense. It is bad politics. And worse policy.
Remember how 340B has always worked: eligible nonprofit healthcare providers get to purchase prescription drugs at discounted prices, helping them generate upfront savings they plow back into care for low-income patients. Congress created the program in 1992 as a means for nonprofit providers to stretch limited federal resources as far as possible to reach more eligible patients with more comprehensive services. Any change from how providers access savings only benefits drug companies aiming to limit the number of prescriptions available at reduced prices.
What makes it worse is that the lawmakers acknowledge that rebate conversion would hurt their providers and constituents, which makes prohibiting the programmatic change the preferred policy solution. Take a look at some of the quotes from the House members touting their new legislation:
“Patients and providers should not have to bear the risks of an untested change to a program that helps deliver affordable medicines to communities across the country,” said Rep. Bresnahan. “Congress needs more time to evaluate the potential financial and administrative consequences of the rebate model and ensure that any changes to 340B protect patients and the providers who serve them.”
“Families in Michigan are already struggling to pay for healthcare,” said Rep. Dingell. “Safety-net providers are not in the financial position to front this money, especially in light of Medicaid cuts, and will either have to hike up prices for patients or stop offering lifesaving drugs. This bill would delay the implementation of this rebate model so we can ensure people’s lives are not put at risk.”
“The new rebate model would force these providers to pay higher upfront costs and wait to be reimbursed, putting unnecessary financial strain on facilities that already operate on tight margins,” said Rep. Mann.
And finally, Rep. Frankel stated, “Our bipartisan bill stops a new requirement forcing these providers to pay full price for prescription drugs and then wait for rebates. Their limited resources should go toward caring for patients, not waiting for drug companies to pay them back.
Even the extremely drug company-friendly SECURE 340B Act introduced by long-term 340B opponent Rep. Scott Peters would delay rebate conversion until four years after his bill became law. If politicians in Congress want to protect their nonprofit providers, they should do more than just postpone a foreseeable terrible outcome.
John Arcano is Senior Manager of Policy and Government Affairs at AIDS Healthcare Foundation.











